Oncoinvent - Public Comps and Valuation Multiples

Oncoinvent Overview

About Oncoinvent

Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The product candidate, Radspherin, uses the alpha-emitting radionuclide radium-224 to directly target micrometastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting.

Founded

2007

HQ

Employees

Website

oncoinvent.com

Sectors

Drug Development & Therapeutics
Biopharmaceuticals
BioTech

Financials

Last FY Revenue $0.1M

Last FY EBITDA -$13.8M

EV

$15.3M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Oncoinvent Financials

See Oncoinvent valuation multiples based on analyst estimates

Oncoinvent P&L

In the most recent fiscal year, Oncoinvent reported revenue of $0.1M and EBITDA of -$13.8M.

Oncoinvent expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Oncoinvent valuation multiples based on analyst estimates

	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	XXX	$0.1M	XXX	XXX	XXX
Gross Profit	XXX	n/a	XXX	XXX	XXX
Gross Margin	XXX	n/a	XXX	XXX	XXX
EBITDA	XXX	-$13.8M	XXX	XXX	XXX
EBITDA Margin	XXX	-16371%	XXX	XXX	XXX
EBIT	XXX	-$15.0M	XXX	XXX	XXX
EBIT Margin	XXX	-17834%	XXX	XXX	XXX
Net Profit	XXX	-$13.9M	XXX	XXX	XXX
Net Margin	XXX	-16425%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Oncoinvent including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Oncoinvent achieved $0.1M in revenue and -$13.8M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	Analyst estimates available to subscribers	$0.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	NaN% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	-$13.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	-16371.0% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	-$15.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	-17834.1% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	-$13.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	-16424.8% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Oncoinvent

This financial data table provides comprehensive performance metrics for Oncoinvent, a company based in Norway. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Oncoinvent reported $0.1M in total revenue.
Fiscal year EBITDA was -$13.8M.
The company maintained a gross profit margin of NaN% in the most recent fiscal year.
EBITDA margin for the fiscal year was -16371.0%.
Net profit margin reached -16424.8% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Oncoinvent. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Oncoinvent Stock Performance

Oncoinvent has current market cap of NOK 220M (or $21.9M), and EV of NOK 154M (or $15.3M).

Market Cap Evolution

Oncoinvent Stock Data

As of January 2, 2026, Oncoinvent's stock price is NOK 0 (or $0).

See Oncoinvent trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$15.3M	$21.9M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Oncoinvent Valuation Multiples

Oncoinvent's trades at 181.6x EV/Revenue multiple, and -1.1x EV/EBITDA.

See valuation multiples for Oncoinvent and 15K+ public comps

Oncoinvent Financial Valuation Multiples

As of January 2, 2026, Oncoinvent has market cap of $21.9M and EV of $15.3M.

Equity research analysts estimate Oncoinvent's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Oncoinvent's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$21.9M	XXX	$21.9M	XXX	XXX	XXX
EV (current)	$15.3M	XXX	$15.3M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	181.6x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-1.1x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	-1.0x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	-1.6x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-1.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Oncoinvent Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Oncoinvent Margins & Growth Rates

Oncoinvent's revenue per employee in the last FY averaged $6K, while opex per employee averaged $1.2M for the same period.

Oncoinvent's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Oncoinvent's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Oncoinvent and other 15K+ public comps

Oncoinvent Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$6K	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	10341%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	17934%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial